Evaluation of phase I clinical trial designs for combinational agents along with guidance based on simulation studies

DOI10.1080/02664763.2022.2105827arXiv2103.07746OpenAlexW4289549851MaRDI QIDQ6109773

No author found.

Publication date: 28 July 2023

Published in: Journal of Applied Statistics (Search for Journal in Brave)

Full work available at URL: https://arxiv.org/abs/2103.07746

zbMATH Keywords

phase I clinical trialdose-findingcombinational agentsguidance for phase I

Mathematics Subject Classification ID

Statistics (62-XX)

Cites Work

• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach
• Bootstrap aggregating continual reassessment method for dose finding in drug-combination trials
• A Bayesian dose-finding design for drug combination trials with delayed toxicities
• Optimal Bayesian-feasible dose escalation for cancer phase I trials
• Operating characteristics of the standard phase I clinical trial design.
• A Bayesian adaptive design in cancer phase I trials using dose combinations in the presence of a baseline covariate
• Continual Reassessment Method for Partial Ordering
• A Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic Agents
• Dose-Finding with Two Agents in Phase I Oncology Trials
• A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents
• Designs for Single- or Multiple-Agent Phase I Trials
• Two‐Dimensional Dose Finding in Discrete Dose Space

This page was built for publication: Evaluation of phase I clinical trial designs for combinational agents along with guidance based on simulation studies